Graviton Bioscience Corporation is a startup based in the United States.
Based in the United States, Graviton Bioscience Corporation is a startup.
Graviton Bioscience Corporation is developing selective ROCK2 inhibitors, including their lead asset GV101, for the treatment of fibrotic and autoimmune diseases such as Graft Versus Host Disease and Idiopathic Pulmonary Fibrosis.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.